Insmed, a Virginia-based firm that seeks to develop a portfolio of follow-on biotech drugs, has worked to educate Congress and lobby for revised laws that would create a pathway for approval of follow-on biologics. The company supports a five-year period of data exclusivity for biotech drugs, but BIO and other companies say a 14-year period is needed to ensure a return on investment and continued incentives for drug development.

Related Summaries